文献速递浆细胞疾病

骨髓涂片胞质轻链免疫荧光联合FISH检测多发性骨髓瘤细胞遗传学异常

[Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

纳入南京医科大学第一附属医院2022年4月至2023年10月收治的42例多发性骨髓瘤患者,采用组合探针同时进行New-FISH与cIg-FISH或MACS-FISH检测。23例中cIg-FISH与New-FISH异常检出率分别为95.7%与100.0%(P>0.05);19例中MACS-FISH与New-FISH分别为73.7%与63.2%(P>0.05)。结论认为New-FISH检出率较高且与两种方法一致性较好。

要点

  • 23例中cIg-FISH异常检出率95.7%,New-FISH为100.0%,差异无统计学意义(P>0.05)。
  • 19例中MACS-FISH异常检出率73.7%,New-FISH为63.2%,差异无统计学意义(P>0.05)。
  • 两法对1q21扩增、1p32缺失、p53缺失、IgH异常检出率一致,分别为52.2%、8.7%、17.4%、65.2%。

核心结论

  • New-FISH法对MM患者细胞遗传学异常检出率较高,与MACS-FISH、cIg-FISH一致性较好。

研究设计与样本

  • 纳入南京医科大学第一附属医院2022年4月至2023年10月收治的42例MM患者。
  • 采用组合探针1q21/1p32、p53、IgH、IgH/FGFR3[t(4;14)]、IgH/MAF[t(14;16)]同时进行New-FISH和MACS-FISH或cIg-FISH检测。

主要发现

  • 23例MM患者中,cIg-FISH法异常检出率为95.7%,New-FISH法为100.0%(P>0.05)。
  • cIg-FISH法与New-FISH法对1q21扩增、1p32缺失、p53缺失、IgH异常的检出率一致,分别为52.2%、8.7%、17.4%、65.2%。
  • 对IgH异常患者进一步检测,t(4;14)阳性率为26.7%,t(14;16)未检出,两种方法检测结果相同。
  • 19例MM患者中,MACS-FISH法异常检出率为73.7%,New-FISH法为63.2%(P>0.05)。
  • MACS-FISH法对1q21扩增、1p32缺失、IgH异常的检出率略高于New-FISH法,但差异均无统计学意义(P值均>0.05)。

关键数值与推荐

  • 23例中cIg-FISH异常检出率95.7% vs New-FISH 100.0%(P>0.05)。
  • cIg-FISH与New-FISH对1q21扩增检出率均为52.2%,对1p32缺失均为8.7%,对p53缺失均为17.4%,对IgH异常均为65.2%。
  • IgH异常患者中t(4;14)阳性率为26.7%,t(14;16)未检出。
  • 19例中MACS-FISH异常检出率73.7% vs New-FISH 63.2%(P>0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the sensitivity of cytoplasmic light-chain immunofluorescence with fluorescence in situ hybridization in bone marrow smears (new FISH) for detecting cytogenetic abnormalities in multiple myeloma (MM) . Methods: 42 MM patients admitted to the First Affiliated Hospital of Nanjing Medical University from April 2022 to October 2023 were enrolled. The patients with MM were detected by new FISH and CD138 immunomagnetic bead sorting technology combined with FISH (MACS-FISH) or cytoplasmic immunoglobulin FISH (cIg-FISH) to analyze cytogenetic detection results using combination probes which included 1q21/1p32, p53, IgH, IgH/FGFR3 [t (4;14) ], and IgH/MAF [t (14;16) ]. Results: In 23 patients with MM, the abnormality detection rates of cIg-FISH and new FISH were 95.7% and 100.0%, respectively (P>0.05). The detection rates of 1q21+, 1p32-, p53 deletion, and IgH abnormalities by cIg-FISH and new FISH were consistent, which were 52.2%, 8.7%, 17.4%, and 65.2%, respectively. The results of the two methods further performed with t (4;14) and t (14;16) in patients with IgH abnormalities were identical. The positive rate of t (4;14) was 26.7%, whereas t (14;16) was not detected. In 19 patients with MM, the abnormality detection rates of MACS-FISH and new FISH were 73.7% and 63.2%, respectively (P>0.05). The positivity rate of 1q21+, 1p32- and IgH abnormalities detected by MACS-FISH were slightly higher than those detected by new FISH; however, the differences were not statistically significant (all P values >0.05) . Conclusion: The new FISH method has a higher detection rate of cytogenetic abnormalities in patients with MM and has good consistency with MACS-FISH and cIg-FISH. 目的: 分析骨髓涂片胞质轻链免疫荧光结合FISH技术(New-FISH)检测多发性骨髓瘤(MM)细胞遗传学异常的敏感性。 方法: 纳入南京医科大学第一附属医院2022年4月至2023年10月收治的42例MM患者,采用组合探针1q21/1p32、p53、IgH、IgH/FGFR3[t(4;14)]、IgH/MAF[t(14;16)]对患者同时进行New-FISH和CD138磁珠分选结合FISH(MACS-FISH)或胞质轻链免疫荧光结合FISH(cIg-FISH)检测,分析其细胞遗传学检测结果。 结果: 23例MM患者中,cIg-FISH法、New-FISH法异常检出率分别为95.7%、100.0%(P>0.05)。cIg-FISH法、New-FISH法对1q21扩增、1p32缺失、p53缺失、IgH异常的检出率一致,分别为52.2%、8.7%、17.4%、65.2%。进一步对IgH异常的患者进行t(4;14)、t(14;16)检测,t(4;14)阳性率为26.7%,t(14;16)未检出,两种方法检测结果相同。19例MM患者中,MACS-FISH法、New-FISH法异常检出率分别为73.7%、63.2%(P>0.05)。MACS-FISH法对1q21扩增、1p32缺失、IgH异常的检出率略高于New-FISH法,但差异均无统计学意义(P值均>0.05)。 结论: New-FISH法对于MM患者细胞遗传学异常检出率较高,与MACS-FISH、cIg-FISH一致性较好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shi Y, Yang H, Guo R, et al. [Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39134488. doi:10.3760/cma.j.cn121090-20231204-00291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。